We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 26, 2026 – Stocks in this week’s article are IPG Photonics (IPGP - Free Report) , Dollar General (DG - Free Report) , Ironwood Pharmaceuticals (IRWD - Free Report) and Science Applications International (SAIC - Free Report) .
4 Stocks Trading Near 52-Week Highs with More Upside Potential
Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and trend reversals.
Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculation is not absolutely baseless, not all stocks hitting a 52-week high are necessarily overpriced.
Investors might lose out on top gainers in an attempt to avoid the steep prices.
Stocks such as IPG Photonics, Dollar General, Ironwood Pharmaceuticals and Science Applications International are expected to maintain their momentum and keep scaling new highs. More information on a stock is necessary to determine whether there is scope for further upside.
Here, we discuss a strategy to find the right stocks. The technique borrows from the basics of momentum investing and bets on “buy high, sell higher.”
52-Week High: A Good Indicator
Many times, stocks that hit a 52-week high fail to scale higher despite having potential. This is because investors fear that the stocks are overvalued and expect the price to crash.
Overvaluation is natural for most of these stocks as investors’ focus (or willingness to pay the premium) has helped them reach this level. But that does not always indicate an impending decline. Factors such as robust sales, surging profit levels, earnings growth prospects and strategic acquisitions, which encouraged investors to bet on these stocks, could keep them motivated if there are no tangible negatives. In other words, the momentum might continue.
Also, when a string of positive developments dominates the market, investors find their underreaction unwarranted, even if there are no company-specific driving forces.
Here are our four picks out of the 20 stocks that made it through the screen:
IPG Photonics positions itself favorably for 2026 growth through strategic expansion and product innovation. The November 2025 opening of its dedicated 14,000-square-foot Huntsville facility establishes IPG Defense as a distinct business unit, capitalizing on the rising demand for CROSSBOW laser defense systems in counter-UAS applications. This expansion into the defense sector diversifies revenue streams beyond traditional materials processing markets.
Meanwhile, January 2026 showcased breakthrough technologies at SPIE Photonics West, including an award-finalist 8-kilowatt compact single-mode laser with exceptional beam quality, advanced nanosecond cleaning systems, and high-power platforms reaching 60 kilowatts. These innovations demonstrate technological leadership across cleaning, welding, cutting, micro-machining and medical applications. The combination of defense market penetration and cutting-edge product development strengthens IPG's competitive positioning for accelerating adoption across multiple end markets.
This Zacks Rank #1 stock has returned 12.5% in the past six-month period. It has a trailing four-quarter earnings surprise of 89.09%, on average. The Zacks Consensus Estimate for IPGP’s 2026 earnings has moved north by 4.7% to $1.55 per share over the past 60 days.
Dollar General presents a compelling investment opportunity driven by robust operational momentum and strategic expansion initiatives. The retailer delivered strong third-quarter results with same-store sales growth of 2.5%, accompanied by matching traffic growth —demonstrating genuine customer engagement. Operating profit surged 31.5%, reflecting improved operational efficiency.
The company raised its fiscal 2025 financial guidance and outlined an ambitious fiscal 2026 real estate expansion plan encompassing approximately 4,730 projects, including 450 new U.S. store openings, primarily targeting underserved rural communities. This footprint expansion, combined with 4,250 store remodels through Project Renovate and Project Elevate initiatives, positions Dollar General to capture incremental market share. The company's value proposition resonates strongly with price-conscious consumers navigating economic uncertainty, while its dividend declaration demonstrates commitment to shareholder returns alongside growth investments.
This Zacks Rank #1 stock has returned 32.4% in the past six-month period. It has a trailing four-quarter earnings surprise of 22.86%, on average. The Zacks Consensus Estimate for DG’s fiscal 2026 earnings has moved north by 5.7% to $7.08 per share over the past 60 days.
Ironwood Pharmaceuticals presents a compelling opportunity driven by strategic pricing optimization and pipeline advancement. The January 2026 LINZESS list price reduction eliminates inflationary rebate penalties, paradoxically driving higher net sales expectations of $1.125-$1.175 billion while supporting patient access. This enhanced margin profile powers projected adjusted EBITDA exceeding $300 million, establishing robust cash generation without dilutive financing needs. The company strengthened its balance sheet to over $200 million in cash while achieving debt covenant compliance.
Importantly, fourth-quarter 2025 FDA alignment on apraglutide's confirmatory Phase 3 trial design clears regulatory uncertainty, with initiation planned for first-half 2026. The ongoing strategic alternatives review further signals management's commitment to maximizing shareholder value. This dual-engine approach—optimizing the LINZESS franchise while self-funding apraglutide's blockbuster potential—positions Ironwood for sustained profitability and growth.
This Zacks Rank #1 stock has surged 521.5% in the past six-month period. It has a trailing four-quarter earnings surprise of 28.95%, on average. The Zacks Consensus Estimate for IRWD’s 2026 earnings has moved north by 65.2% to 76 cents per share over the past 60 days.
Science Applications International Corp. is positioned for growth through strategic organizational restructuring and significant contract wins. The consolidation of five business groups into three streamlined divisions, effective Jan. 31, 2026, aims to optimize operations and sharpen customer focus for sustainable value creation. The company secured a substantial $1.4 billion COBRA task order in November 2025 to accelerate multi-domain warfighting technologies across Combined Joint All-Domain Command and Control systems, demonstrating strong positioning in defense modernization.
December 2025 saw a $242 million Navy contract for undersea weapon facility operations and recognition as an IDC MarketScape Leader in AI services for both defense/intelligence and civilian government sectors. With a robust $23.8 billion backlog and a year-to-date book-to-bill ratio of 1.3, fundamental momentum supports continued operational strength.
This Zacks Rank #1 stock has lost 6% in the past six-month period. It has a trailing four-quarter earnings surprise of 26.05%, on average. The Zacks Consensus Estimate for SAIC’s fiscal 2026 earnings has moved north by 3.9% to $9.96 per share over the past 60 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications
For Immediate Release
Chicago, IL – January 26, 2026 – Stocks in this week’s article are IPG Photonics (IPGP - Free Report) , Dollar General (DG - Free Report) , Ironwood Pharmaceuticals (IRWD - Free Report) and Science Applications International (SAIC - Free Report) .
4 Stocks Trading Near 52-Week Highs with More Upside Potential
Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and trend reversals.
Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculation is not absolutely baseless, not all stocks hitting a 52-week high are necessarily overpriced.
Investors might lose out on top gainers in an attempt to avoid the steep prices.
Stocks such as IPG Photonics, Dollar General, Ironwood Pharmaceuticals and Science Applications International are expected to maintain their momentum and keep scaling new highs. More information on a stock is necessary to determine whether there is scope for further upside.
Here, we discuss a strategy to find the right stocks. The technique borrows from the basics of momentum investing and bets on “buy high, sell higher.”
52-Week High: A Good Indicator
Many times, stocks that hit a 52-week high fail to scale higher despite having potential. This is because investors fear that the stocks are overvalued and expect the price to crash.
Overvaluation is natural for most of these stocks as investors’ focus (or willingness to pay the premium) has helped them reach this level. But that does not always indicate an impending decline. Factors such as robust sales, surging profit levels, earnings growth prospects and strategic acquisitions, which encouraged investors to bet on these stocks, could keep them motivated if there are no tangible negatives. In other words, the momentum might continue.
Also, when a string of positive developments dominates the market, investors find their underreaction unwarranted, even if there are no company-specific driving forces.
Here are our four picks out of the 20 stocks that made it through the screen:
IPG Photonics positions itself favorably for 2026 growth through strategic expansion and product innovation. The November 2025 opening of its dedicated 14,000-square-foot Huntsville facility establishes IPG Defense as a distinct business unit, capitalizing on the rising demand for CROSSBOW laser defense systems in counter-UAS applications. This expansion into the defense sector diversifies revenue streams beyond traditional materials processing markets.
Meanwhile, January 2026 showcased breakthrough technologies at SPIE Photonics West, including an award-finalist 8-kilowatt compact single-mode laser with exceptional beam quality, advanced nanosecond cleaning systems, and high-power platforms reaching 60 kilowatts. These innovations demonstrate technological leadership across cleaning, welding, cutting, micro-machining and medical applications. The combination of defense market penetration and cutting-edge product development strengthens IPG's competitive positioning for accelerating adoption across multiple end markets.
This Zacks Rank #1 stock has returned 12.5% in the past six-month period. It has a trailing four-quarter earnings surprise of 89.09%, on average. The Zacks Consensus Estimate for IPGP’s 2026 earnings has moved north by 4.7% to $1.55 per share over the past 60 days.
Dollar General presents a compelling investment opportunity driven by robust operational momentum and strategic expansion initiatives. The retailer delivered strong third-quarter results with same-store sales growth of 2.5%, accompanied by matching traffic growth —demonstrating genuine customer engagement. Operating profit surged 31.5%, reflecting improved operational efficiency.
The company raised its fiscal 2025 financial guidance and outlined an ambitious fiscal 2026 real estate expansion plan encompassing approximately 4,730 projects, including 450 new U.S. store openings, primarily targeting underserved rural communities. This footprint expansion, combined with 4,250 store remodels through Project Renovate and Project Elevate initiatives, positions Dollar General to capture incremental market share. The company's value proposition resonates strongly with price-conscious consumers navigating economic uncertainty, while its dividend declaration demonstrates commitment to shareholder returns alongside growth investments.
This Zacks Rank #1 stock has returned 32.4% in the past six-month period. It has a trailing four-quarter earnings surprise of 22.86%, on average. The Zacks Consensus Estimate for DG’s fiscal 2026 earnings has moved north by 5.7% to $7.08 per share over the past 60 days.
Ironwood Pharmaceuticals presents a compelling opportunity driven by strategic pricing optimization and pipeline advancement. The January 2026 LINZESS list price reduction eliminates inflationary rebate penalties, paradoxically driving higher net sales expectations of $1.125-$1.175 billion while supporting patient access. This enhanced margin profile powers projected adjusted EBITDA exceeding $300 million, establishing robust cash generation without dilutive financing needs. The company strengthened its balance sheet to over $200 million in cash while achieving debt covenant compliance.
Importantly, fourth-quarter 2025 FDA alignment on apraglutide's confirmatory Phase 3 trial design clears regulatory uncertainty, with initiation planned for first-half 2026. The ongoing strategic alternatives review further signals management's commitment to maximizing shareholder value. This dual-engine approach—optimizing the LINZESS franchise while self-funding apraglutide's blockbuster potential—positions Ironwood for sustained profitability and growth.
This Zacks Rank #1 stock has surged 521.5% in the past six-month period. It has a trailing four-quarter earnings surprise of 28.95%, on average. The Zacks Consensus Estimate for IRWD’s 2026 earnings has moved north by 65.2% to 76 cents per share over the past 60 days.
Science Applications International Corp. is positioned for growth through strategic organizational restructuring and significant contract wins. The consolidation of five business groups into three streamlined divisions, effective Jan. 31, 2026, aims to optimize operations and sharpen customer focus for sustainable value creation. The company secured a substantial $1.4 billion COBRA task order in November 2025 to accelerate multi-domain warfighting technologies across Combined Joint All-Domain Command and Control systems, demonstrating strong positioning in defense modernization.
December 2025 saw a $242 million Navy contract for undersea weapon facility operations and recognition as an IDC MarketScape Leader in AI services for both defense/intelligence and civilian government sectors. With a robust $23.8 billion backlog and a year-to-date book-to-bill ratio of 1.3, fundamental momentum supports continued operational strength.
This Zacks Rank #1 stock has lost 6% in the past six-month period. It has a trailing four-quarter earnings surprise of 26.05%, on average. The Zacks Consensus Estimate for SAIC’s fiscal 2026 earnings has moved north by 3.9% to $9.96 per share over the past 60 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2822050/4-stocks-trading-near-52-week-high-with-more-upside-potential?art_rec=quote-stock_overview-zacks_news-ID02-txt-2822050
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.